Intervention

Pioglitazone

ClinicalTrials.gov intervention label

Clinical trials159

Recruiting10

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or TirzepatideNCT06657209 · 2025-01-13

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset DiabetesNCT06246799 · 2024-11-07

Enavogliflozin vs. Pioglitazone on Glucose and AtherosclerosisNCT06399835 · 2024-02-01

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus ParticipantsNCT05838287 · 2023-07-10

A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.NCT05753657 · 2022-12-25

Quantifying Hepatic Mitochondrial Fluxes in HumansNCT05305287 · 2022-11-01

Low-Dose Pioglitazone in Patients With NASH (AIM 2)NCT04501406 · 2020-12-15

Insulin Regulation of Lipolysis and Lipolysis ProteinsNCT03866408 · 2018-11-12

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)NCT03109288 · 2017-08-11

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)NCT02969798 · 2014-01-01

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy ParticipantsNCT07444424 · 2026-03-13

Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver DiseaseNCT05422092 · 2022-09-20

Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver DiseaseNCT05513729 · 2022-08-18

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty LiverNCT04976283 · 2021-09-15

Targeting Beta-cell Failure in Lean Patients With Type 2 DiabetesNCT04657939 · 2020-12-01

GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot StudyNCT04473274 · 2020-05-21

Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver DiseasesNCT03910361 · 2019-04-12

Antidiabetic Drugs for Steatotic Liver DiseaseNCT03646292 · 2018-12-06

Pioglitazone to Reduce Sympathetic Overactivity in CKD PatientsNCT03471117 · 2018-04-01

Study of NGM313 in Obese ParticipantsNCT03298464 · 2017-09-11

HbA1c Variability in Type II DiabetesNCT02879409 · 2016-11-01

ACTIVE_NOT_RECRUITING

Brown Fat Activation StudyNCT02919176 · 2016-09-01

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During RamadanNCT02694263 · 2016-07-01

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate CancerNCT02592317 · 2016-02-12

ACTIVE_NOT_RECRUITING

A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLCNCT02852083 · 2016-01-01

A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover MarkersNCT02429232 · 2015-10-01

Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)NCT02535832 · 2015-09-01

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer DiseaseNCT02284906 · 2015-02-12

Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus AlogliptinNCT02426294 · 2015-02-01

Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes MellitusNCT02303405 · 2014-11-01

A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr DiseaseNCT02265276 · 2014-10-01

The Practical Evidence of Antidiabetic Combination Therapy in KoreaNCT02231021 · 2014-09-01

Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes ManagementNCT02315287 · 2014-09-01

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)NCT02072096 · 2014-02-01

Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral TherapyNCT01972724 · 2013-12-16

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its OnsetNCT01931566 · 2013-08-01

Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"NCT01935466 · 2013-07-01

Triple Therapy in Type 2 Diabetic PatientsNCT01895569 · 2013-06-01

Fatty Liver Study in Patients With Type II DiabetesNCT02365233 · 2013-05-01

Mediators of Abnormal Reproductive Function in Obesity (MARO)NCT01817400 · 2013-03-01

Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes PatientsNCT01963663 · 2012-11-01

Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes PatientsNCT02027103 · 2012-01-01

Pioglitazone in Patients With Mood DisordersNCT01559857 · 2011-11-01

Drug-drug Interaction Study With MDV3100 and a Cocktail of SubstratesNCT01911728 · 2011-07-25

Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes PatientsNCT01593371 · 2011-07-01

Metabolic Abnormalities in HIV-infected PersonsNCT01612858 · 2011-06-01

Pioglitazone in Early Parkinson's DiseaseNCT01280123 · 2011-03-01

Cellular Dynamics of Subcutaneous Fat Distribution in Obese WomenNCT01748994 · 2011-02-01

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic PatientsNCT01280695 · 2011-02-01

Efficacy and Safety of Alogliptin in Participants With Type 2 DiabetesNCT01289119 · 2010-12-01

A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)NCT01217073 · 2010-10-08

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic PatientsNCT01225081 · 2010-09-15

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic PatientsNCT01103414 · 2010-09-01

Obesity, Sleep Apnea, and Insulin ResistanceNCT02192684 · 2010-09-01

Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic PatientsNCT01147627 · 2010-08-01

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin AloneNCT01095666 · 2010-06-01

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)NCT01106690 · 2010-06-01

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes MellitusNCT01082120 · 2010-02-01

A Study in Participants With Type 2 Diabetes MellitusNCT01064687 · 2010-02-01

Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?NCT01040819 · 2010-02-01

Common conditions

Leading sponsors

Takeda31 The University of Texas Health Science Center at San Antonio8 AstraZeneca6 Stanford University4 Daiichi Sankyo3 Merck Sharp & Dohme LLC3 Metabolic Solutions Development Company3 National Institute of Allergy and Infectious Diseases (NIAID)3 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)3 Pennington Biomedical Research Center3 Tehran University of Medical Sciences3 Baylor College of Medicine2 Eli Lilly and Company2 First Affiliated Hospital Xi'an Jiaotong University2 Philip Kern2

Trial status mix

COMPLETED114

TERMINATED16

UNKNOWN15

RECRUITING10

ACTIVE_NOT_RECRUITING2

WITHDRAWN2

Phase mix

PHASE451

PHASE337

PHASE232

NA22

PHASE19

EARLY_PHASE14

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.